REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today

Coherus Oncology, Inc. (NASDAQ:CHRS) ("Coherus", "Coherus Oncology" or the "Comp

– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Compl

Guggenheim analyst Paul Jeng maintains Coherus Oncology (NASDAQ:CHRS) with a Buy and lowers the p

Coherus Oncology, Inc. (CHRS) Q2 2026 Earnings Call Transcript

Coherus Oncology NASDAQ: CHRS said it is approaching several clinical data disclosures in the second

Coherus Oncology (CHRS) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.19) per share which beat the anal

– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – – Clinical data continue to ma

REDWOOD CITY, Calif. , July 22, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), toda

Coherus Oncology, Inc. (NASDAQ:CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncol

– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQ

Coherus Oncology (CHRS) remains a Buy as I maintain optimism around its advancing immunotherapy pipe

Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript

Coherus Oncology NASDAQ: CHRS said it expects revenue growth for its nasopharyngeal cancer drug LOQT

Coherus Oncology (CHRS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.25) per share which beat the anal

– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2

Guggenheim initiates coverage on Coherus Oncology (NASDAQ:CHRS) with a Buy rating and announces Pr

Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as

REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today

Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abou

Shares of Coherus Oncology, Inc. (NASDAQ: CHRS - Get Free Report) have received an average rating of

Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript

Coherus Oncology (CHRS) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus

Coherus BioSciences (NASDAQ:CHRS) reported quarterly losses of $(0.34) per share which met the analy

– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Re

In addition, Coherus intends to grant the underwriters a 30-day option to purchase additional shares

4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improvin

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarte

Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of

U.S. stocks traded slightly higher, with the Dow Jones index gaining over 20 points on Wednesday. S